Gilead Sciences (GILD) stock: key figures, P/E, revenue and dividend
Health Care · Biotechnology · United States · ISIN US3755581036
Gilead Sciences financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 29.44 bn USD |
| Gross profit | 23.21 bn USD |
| Operating income | 10.02 bn USD |
| EBIT | 10.82 bn USD |
| Net income | 8.51 bn USD |
| Diluted EPS – continuing operations | 6.78 USD |
Full history since 1990, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Gilead Sciences
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
More stocks
- Bayan Resources Tbk (BYAN.JK)
- Vireo Growth Inc. (VREOF)
- Toronto-Dominion Bank (TD.TO)
- TotalEnergies SE (TTE.PA)
- Analog Devices (ADI)
- Salesforce (CRM)
- Industria de Diseno Textil SA (ITX.MC)
- Contemporary Amperex Technology Co Ltd Class A (300750.SZ)
- Walt Disney Company (The) (DIS)
- Verizon (VZ)
- Allianz (ALV.DE)
- Commonwealth Bank of Australia (CBA.AX)
Not investment advice. All data without warranty, price as of 14.10.2026. Details in the risk notice.